Liberty Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$8,232	2
2024	Research	$9,052	2
2023	Research	$21,332	3
2022	Research	$25,306	9
2021	Research	$427,671	65
2020	Research	$114,007	84

Breakdown

Who paid Research payments · program years 2020–2025

GlaxoSmithKline, LLC. $556,797 156 payments
Novartis Pharmaceuticals Corporation $32,364 5 payments
Bayer HealthCare Pharmaceuticals Inc. $16,440 4 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $556,797 156 payments
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of Lnp023 in Primary Iga Nephropathy Patients $23,364 3 payments
BAY94-8862, Finerenone Phase 3 in non-diabetic CKD $12,266 3 payments
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy $4,500 1 payment
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-Of-Care Therapy in Patients With Active Lupus $4,500 1 payment
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic $4,174 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.